Online ISSN: 2348-8727
CODEN : JDP
The Journal of Dental Panacea (JDP) open access, peer-reviewed quarterly journal, Publish quarterly as Open Access (OA). Vision of this journal for better dissemination of knowledge, Journal will be publishing the article ‘Ahead of Print’ immediately on acceptance. In addition, the journal would allow free access (Open Access) to its contents, which is likely to attract more readers and citations to articles published in JDP. Manuscripts must be prepared in accordance with “Uniform requirements” of the The Journal of Dental Panacea as more...Original Article
Author Details :
Volume : 6, Issue : 4, Year : 2024
Article Page : 193-196
https://doi.org/10.18231/j.jdp.2024.039
Abstract
Background: Androgenetic alopecia is the most common cause of hair loss, affecting self-esteem and quality of life. While platelet-rich plasma has been a standard treatment, it yields inconsistent results due to patient variability. QR678 Neo, a biomimetic peptide-based treatment, offers a standardized alternative.
Aims and Objectives: This study aimed to compare the efficacy and safety profiles of QR678 Neo and platelet-rich plasma in treating androgenetic alopecia. Objectives included evaluating improvements in hair density, hair quality, patient satisfaction, and reduction in hair fall.
Materials and Methods: This retrospective study compared the efficacy of QR678 Neo and platelet-rich plasma in 70 AGA patients. The study evaluated hair density, quality, and patient satisfaction over 6 months.
Results: QR678 Neo showed a 30% improvement in hair density versus 18% with platelet-rich plasma (p<0>
Conclusion: QR678 Neo outperformed PRP in all evaluated parameters, offering a consistent and effective alternative for Androgenetic alopecia treatment.
Keywords: QR678 Neo, Platelet rich plasma, Androgenetic alopecia, Hair regrowth, Biomimetic peptides
How to cite : Nazar J, Singhai S, Comparison between QR678 neo and platelet rich plasma for hair growth -A retrospective study. J Dent Panacea 2024;6(4):193-196
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 International License, which allows others to remix, and build upon the work, the licensor cannot revoke these freedoms as long as you follow the license terms.